Back to Authors

Shosha, Eslam

https://orcid.org/0000-0001-6959-2882

A5080779706 | I195631090

Mayo Clinic

Majmaah University

Citations 7

Myelin Oligodendrocyte Glycoprotein Autoantibody Myelitis; Clinical characteristics, MRI clues and discriminators from other demyelinating myelitis etiologies (S21.005)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s21.005

A Population-Based Study of Idiopathic Transverse Myelitis with Aquaporin-4-IgG and Myelin-Oligodendrocyte-Glycoprotein-IgG Assessment (S11.007)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s11.007

Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) (P6.386)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p6.386

Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology

Neurology | June 25, 2019 | Volume: 93 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000007828 | PMID 31235660

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody

JAMA Neurology | December 21, 2018 | Volume: 76 | Issue: 3 | Pages: 301

10.1001/jamaneurol.2018.4053 | PMID 30575890

Area postrema syndrome

Neurology | September 26, 2018 | Volume: 91 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000006392 | PMID 30258024

Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management

Multiple Sclerosis Journal | November 20, 2017 | Volume: 23 | Issue: 14 | Pages: 1808-1817

10.1177/1352458517740215 | PMID 29154728

Neuromyelitis optica spectrum disorders (NMOSD) predominantly affect women who are of childbearing age. Understanding the interactions between pregnancy and NMOSD is important for clinical management. Aquaporin-4 (AQP4), the most common target antigen in NMOSD, is expressed on placenta in early pregnancy. A variety of immune and cytokine changes in pregnancy may impact pregnancy outcomes in NMOSD patients. Relapses continue during pregnancy and increase in frequency postpartum. Preeclampsia and fetal loss are more frequent in NMOSD than in controls. Transfer of AQP4-immunoglobulin G (IgG) from mother to baby occurs but appears not to cause disease. Several treatment options are relatively safe and mitigate the risk of relapse during pregnancy and postpartum. For patients with active NMOSD, it may be advisable to continue immunotherapy during pregnancy.